<?xml version="1.0" encoding="UTF-8"?>
<p>From HIV programmesâ€™ point of view, the decrease in international funding pushes programmes to make difficult choices: should we favour the purchase of first-line drugs to treat all new patients in a test and treat perspective or rather second-line drugs, knowing that second-line drugs cost about two to five times more than first-line drugs?</p>
